Evidence map›Paper›PMID 39618410›Full record

ArticleHypertension (Dallas, Tex. : 1979)2025

Peli1 Deficiency in Macrophages Attenuates Pulmonary Hypertension by Enhancing Foxp1-Mediated Transcriptional Inhibition of IL-6.

Donghai Lin, Li Hu, Dong Wei, Yan Li, Yanfang Yu, Qiang Wang, Xiaoxuan Sun, Yueyao Shen, Youjia Yu, Kai Li and 9 more

Abstract read
PubMed Publisher
In one paragraph

Article in Hypertension (Dallas, Tex. : 1979), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors.

Donghai Lin *Department of Forensic Medicine (D.L., L.H., Yan Li, Yanfang Yu, Y.S., Youjia Yu, K.L., Z.Z., Y.C., J.W., H.H., F.C.), Nanjing Medical University, China.
Li Hu *Department of Forensic Medicine (D.L., L.H., Yan Li, Yanfang Yu, Y.S., Youjia Yu, K.L., Z.Z., Y.C., J.W., H.H., F.C.), Nanjing Medical University, China.ORCID 0000-0002-7535-6453
Dong Wei *The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's Hospital, Wuxi Medical Center (D.W., J.C., F.C.), Nanjing Medical University, China.ORCID 0000-0002-4829-3258
Yan LiDepartment of Forensic Medicine (D.L., L.H., Yan Li, Yanfang Yu, Y.S., Youjia Yu, K.L., Z.Z., Y.C., J.W., H.H., F.C.), Nanjing Medical University, China.
Yanfang YuDepartment of Forensic Medicine (D.L., L.H., Yan Li, Yanfang Yu, Y.S., Youjia Yu, K.L., Z.Z., Y.C., J.W., H.H., F.C.), Nanjing Medical University, China.
Qiang WangDepartment of Rheumatology, First Affiliated Hospital of Nanjing Medical University, China (Q.W., X.S.).
Xiaoxuan SunDepartment of Rheumatology, First Affiliated Hospital of Nanjing Medical University, China (Q.W., X.S.).
Yueyao ShenDepartment of Forensic Medicine (D.L., L.H., Yan Li, Yanfang Yu, Y.S., Youjia Yu, K.L., Z.Z., Y.C., J.W., H.H., F.C.), Nanjing Medical University, China.
Youjia YuDepartment of Forensic Medicine (D.L., L.H., Yan Li, Yanfang Yu, Y.S., Youjia Yu, K.L., Z.Z., Y.C., J.W., H.H., F.C.), Nanjing Medical University, China.
Kai LiDepartment of Forensic Medicine (D.L., L.H., Yan Li, Yanfang Yu, Y.S., Youjia Yu, K.L., Z.Z., Y.C., J.W., H.H., F.C.), Nanjing Medical University, China.
Zhiwei ZhangDepartment of Forensic Medicine (D.L., L.H., Yan Li, Yanfang Yu, Y.S., Youjia Yu, K.L., Z.Z., Y.C., J.W., H.H., F.C.), Nanjing Medical University, China.
Yue CaoDepartment of Forensic Medicine (D.L., L.H., Yan Li, Yanfang Yu, Y.S., Youjia Yu, K.L., Z.Z., Y.C., J.W., H.H., F.C.), Nanjing Medical University, China.ORCID 0000-0002-0681-0069
Jiantao LiKey Laboratory of Targeted Intervention of Cardiovascular Disease, Collaborative Innovation Center for Cardiovascular Disease Translational Medicine (L.H., J.L., Yuehua Li, J.W., F.C.), Nanjing Medical University, China.ORCID 0009-0008-3487-7915
Yuehua LiKey Laboratory of Targeted Intervention of Cardiovascular Disease, Collaborative Innovation Center for Cardiovascular Disease Translational Medicine (L.H., J.L., Yuehua Li, J.W., F.C.), Nanjing Medical University, China.
David FultonVascular Biology Center, Medical College of Georgia at Augusta University, GA (D.F., F.C.).ORCID 0000-0002-1528-1517
Jingyu ChenThe Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's Hospital, Wuxi Medical Center (D.W., J.C., F.C.), Nanjing Medical University, China.
Jie WangDepartment of Forensic Medicine (D.L., L.H., Yan Li, Yanfang Yu, Y.S., Youjia Yu, K.L., Z.Z., Y.C., J.W., H.H., F.C.), Nanjing Medical University, China.ORCID 0000-0001-5259-7054
Huijie HuangDepartment of Forensic Medicine (D.L., L.H., Yan Li, Yanfang Yu, Y.S., Youjia Yu, K.L., Z.Z., Y.C., J.W., H.H., F.C.), Nanjing Medical University, China.
Feng ChenDepartment of Forensic Medicine (D.L., L.H., Yan Li, Yanfang Yu, Y.S., Youjia Yu, K.L., Z.Z., Y.C., J.W., H.H., F.C.), Nanjing Medical University, China.ORCID 0000-0003-3508-8834

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe infiltration of macrophages into the lungs is a common characteristic of perivascular inflammation, contributing to vascular remodeling in pulmonary hypertension (PH). Peli1 (pellino E3 ubiquitin-protein ligase 1) plays a critical role in regulating the production of proinflammatory cytokines and the polarization of macrophages in various diseases. However, the role of Peli1 in PH remains to be investigated.

methodsThe expression and biological function of Peli1 were investigated in both human and experimental models of PH. Peli1-deficient mice and bone marrow transplant mice were utilized to explore the roles of Peli1 in macrophages in vivo. Proteomic analysis and molecular biology techniques were used to uncover the underlying mechanisms.

resultsThe upregulation of Peli1 in the lungs and alveolar macrophages was observed in hypoxia-treated mice. Peli1 knockout mice and myeloid Peli1-deficient mice significantly ameliorated hypoxia-induced right ventricular systolic pressure, right ventricular hypertrophy, and pulmonary vascular remodeling. Mechanistically, Peli1 facilitated the ubiquitination and subsequent proteasomal degradation of Foxp1 (forkhead box p1), thereby alleviating its suppression of

conclusionsOur findings demonstrate that the Peli1-Foxp1-IL-6 pathway plays a crucial role in macrophage activation and recruitment during the development of PH, underscoring the potential of Peli1 as a therapeutic target for PH.

Indexed as

Forkhead Transcription FactorsHypertension, PulmonaryInterleukin-6MacrophagesMacrophages, AlveolarNuclear ProteinsRepressor ProteinsUbiquitin-Protein LigasesAnimalsDisease Models, AnimalGene Expression RegulationHumansMaleMiceMice, Inbred C57BLMice, KnockoutForkhead Transcription FactorsFoxp1 protein, mouseInterleukin-6Nuclear ProteinsPeli1 protein, mouseRepressor ProteinsUbiquitin-Protein Ligaseshypertension, pulmonaryinflammationinterleukinmacrophagemice

Identifiers

PMID39618410

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.